Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects

References

• Barlesi F, Dingemans A-MC, Ou S-HI, et al. (2015). Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK + non-small-cell lung cancer (NSCLC). Eur J Cancer 51:Abstr. 3101. [ECC 2015]
   Web of Science ®Google Scholar
• Camidge DR, Bang YJ, Kwak EL, et al. (2012). Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13:1011–19
   PubMed Web of Science ®Google Scholar
• Chiarle R, Voena C, Ambrogio C, et al. (2008). The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11–23
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• EMEA (2008). Note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals (CPMP/ICH/286/95). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002941.pdf [last accessed Sep 2015]
   Google Scholar
• FDA (2014). Summary review 205755. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000SumR.pdf [last accessed Sep 2015]
   Google Scholar
• FDA (2016). Clinical pharmacology and biopharmaceutics review(s) of alectinib. US Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000ClinPharmR.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000PharmR.pdf [last accessed 4 Feb 2016]
   Google Scholar
• Gabrielsson J, Weiner D. (2007). Pharmacokinetic and pharmacodynamic data analysis: concepts and applications (review). In: Kristianstads Boktryckeri AB, ed. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. Sweden: Swedish Pharmaceutical Press, 173
   Google Scholar
• Gadgeel SM, Gandhi L, Riely GJ, et al. (2014). Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119–28
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Shaw AT, Govindan R, et al. (2015). Pooled analysis of CNS response to alectinib in two studies of pre-treated ALK + NSCLC. J Thorac Oncol 10:Abstr. 1219. [WCLC 2015]
   PubMed Web of Science ®Google Scholar
• Gandhi L, Shaw A, Gadgeel S, et al. (2015). A phase 2, open-label, multicenter study of the ALK inhibitor alectinib in an ALK + non-small-cell lung cancer (NSCLC) US/Canadian population who had progressed on crizotinib (NP28761). J Clin Oncol 33: Abstr. 8019. [ASCO 2015]
   PubMed Web of Science ®Google Scholar
• Graham RA, Hop C, Borin MT, et al. (2012). Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol 74:788–96
   PubMed Web of Science ®Google Scholar
• ICRP (1992). Recommendations of the International Commission on Radiological Protection. User's ICRP Publication 60. Pergamon Press
   Google Scholar
• Johnson TR, Tan W, Goulet L, et al. (2015). Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. Xenobiotica 45:45–59
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Asoh K, Furuichi N, et al. (2012). Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitors (CH5424802). Bioorg Med Chem 20:1271–80
   PubMed Web of Science ®Google Scholar
• Kodama T, Hasegawa M, Takanashi K, et al. (2014a). Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74:1023–8. [Patternmatch]
   PubMed Web of Science ®Google Scholar
• Kodama T, Tsukaguchi T, Hasegawa M, et al. (2014b). Selective ALK inhibitor CH5424802/alectinib with potent antitumor activity in models of crizotinib resistance, including intracranial metastases. Cancer Res 74:Abstr. 754 [AACR 2014]
   Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–703
   PubMed Web of Science ®Google Scholar
• Lappin G. (2016). Approaches to intravenous clinical pharmacokinetics: recent developments with isotopic microtracers. J Clin Pharmacol 56:11–23
   PubMed Web of Science ®Google Scholar
• Morcos PN, Dall G, Parrott N, et al. (2016a). Effect of food and the proton pump inhibitor (PPI) esomeprazole on the pharmacokinetics (PK) of alectinib, a highly selective ALK inhibitor, in healthy subjects. Clin Pharmacol Ther 99:Abstract PI-120
   Web of Science ®Google Scholar
• Morcos PN, Cleary Y, Dall G, et al. (2016b). Clinical drug–drug interactions (DDIs) through cytochrome P450 3A (CYP3A) for alectinib, a highly selective ALK inhibitor. Clin Pharmacol Ther 99:Abstract PI-119
   Web of Science ®Google Scholar
• Morcos PN, Parrott N, Dall G, et al. (2016c). Effect of the wetting agent sodium lauryl sulfate (SLS) on the pharmacokinetics (PK) of alectinib: results from a bioequivalence (BE) study of healthy subject. Clin Pharmacol Ther 99:Abstract PI-121
   Web of Science ®Google Scholar
• Morcos PN, Yu L, Nieforth K, et al. (2016d). Absorption, distribution, metabolism, and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability/mass balance study in healthy subjects. Clin Pharmacol Ther 99:Abstract PI-118
   Web of Science ®Google Scholar
• Nakagawa T, Takanashi K, Hoshino-Yoshino A, et al. (2016). In vitro metabolism of alectinib, a novel highly potent ALK inhibitor: contribution of CYP3A enzymes in microsomes and hepatocytes. Accepted at International Society for the Study of Xenobiotics (ISSX) 12–16 June 2016
   Google Scholar
• Ou S-HI, Ahn JS, De Petris L, et al. (2016). Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 17:661–8
   Web of Science ®Google Scholar
• Penner N, Klunk LJ, Prakash C. (2009). Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30:185–203
   PubMed Web of Science ®Google Scholar
• Roskoski R. Jr. (2013). Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res 68:68–94
   PubMed Web of Science ®Google Scholar
• Rubin GM, Waschek JA, Pond SM, et al. (1987). Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism. J Pharmacokinet Biopharm 15:615–31
   PubMedGoogle Scholar
• Sato M, Kawashima K, Nakagawa T, et al. (2016). Identification and structure characterization of metabolites in human following a single oral administration of [14c]-alectinib: overcoming the low sensitivity levels of the conventional LC-LSC method for plasma. Accepted at International Society for the Study of Xenobiotics (ISSX) 12–16 June 2016
   Google Scholar
• Sakamoto H, Tsukaguchi T, Hiroshima S, et al. (2011). CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19:679–90
   PubMed Web of Science ®Google Scholar
• Sarapa N, Hsyu PH, Lappin G, Garner RC. (2005). The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-Nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 45:1198–205
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–94
   PubMed Web of Science ®Google Scholar
• Shaw AT, Gandhi L, Gadgeel S, et al. (2016). Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17:234–42
   PubMed Web of Science ®Google Scholar
• Shinmura K, Kageyama S, Tao H, et al. (2008). EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61:163–9
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–6
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Yeo KR, et al. (2007). Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos 35:501–2
   PubMed Web of Science ®Google Scholar